• Product name

    Anti-Cytokeratin 1 antibody [LL017]
    See all Cytokeratin 1 primary antibodies
  • Description

    Mouse monoclonal [LL017] to Cytokeratin 1
  • Host species

  • Tested applications

    Suitable for: IHC-Frmore details
  • Species reactivity

    Reacts with: Human
  • General notes

    ab18389 has not been shown to react with any tumor tissue regardless of histological classification.



Our Abpromise guarantee covers the use of ab18389 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use at an assay dependent concentration.

See paper by Ishida-Yamamoto A et al. Freeze tissue in isopentane over liquid nitrogen and cut cryostat sections. Dilute antibody in 1% BSA, 1% normal serum, 0.1% gelatin and incubate for 2-4 hrs at 37°C.


  • Function

    May regulate the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein kinase C (RACK1/GNB2L1).
  • Tissue specificity

    The source of this protein is neonatal foreskin. The 67-kDa type II keratins are expressed in terminally differentiating epidermis.
  • Involvement in disease

    Defects in KRT1 are a cause of bullous congenital ichthyosiform erythroderma (BCIE) [MIM:113800]; also known as epidermolytic hyperkeratosis (EHK) or bullous erythroderma ichthyosiformis congenita of Brocq. BCIE is an autosomal dominant skin disorder characterized by widespread blistering and an ichthyotic erythroderma at birth that persist into adulthood. Histologically there is a diffuse epidermolytic degeneration in the lower spinous layer of the epidermis. Within a few weeks from birth, erythroderma and blister formation diminish and hyperkeratoses develop.
    Defects in KRT1 are the cause of ichthyosis hystrix Curth-Macklin type (IHCM) [MIM:146590]. IHCM is a genodermatosis with severe verrucous hyperkeratosis. Affected individuals manifest congenital verrucous black scale on the scalp, neck, and limbs with truncal erythema, palmoplantar keratoderma and keratoses on the lips, ears, nipples and buttocks.
    Defects in KRT1 are a cause of palmoplantar keratoderma non-epidermolytic (NEPPK) [MIM:600962]. NEPKK is a dermatological disorder characterized by focal palmoplantar keratoderma with oral, genital, and follicular lesions.
    Defects in KRT1 are a cause of ichthyosis annular epidermolytic (AEI) [MIM:607602]; also known as cyclic ichthyosis with epidermolytic hyperkeratosis. AEI is a skin disorder resembling bullous congenital ichthyosiform erythroderma. Affected individuals present with bullous ichthyosis in early childhood and hyperkeratotic lichenified plaques in the flexural areas and extensor surfaces at later ages. The feature that distinguishes AEI from BCIE is dramatic episodes of flares of annular polycyclic plaques with scale, which coalesce to involve most of the body surface and can persist for several weeks or even months.
    Defects in KRT1 are the cause of palmoplantar keratoderma striate type 3 (SPPK3) [MIM:607654]; also known as keratosis palmoplantaris striata III. SPPK3 is a dermatological disorder affecting palm and sole skin where stratum corneum and epidermal layers are thickened. There is no involvement of non-palmoplantar skin, and both hair and nails are normal.
  • Sequence similarities

    Belongs to the intermediate filament family.
  • Post-translational

    Undergoes deimination of some arginine residues (citrullination).
  • Cellular localization

    Cell membrane. Located on plasma membrane of neuroblastoma NMB7 cells.
  • Information by UniProt
  • Database links

  • Alternative names

    • 67 kDa cytokeratin antibody
    • CK-1 antibody
    • CK1 antibody
    • Cytokeratin-1 antibody
    • Cytokeratin1 antibody
    • EHK antibody
    • EHK1 antibody
    • Epidermolytic hyperkeratosis 1 antibody
    • EPPK antibody
    • Hair alpha protein antibody
    • K1 antibody
    • K2C1_HUMAN antibody
    • Keratin antibody
    • Keratin type II cytoskeletal 1 antibody
    • Keratin-1 antibody
    • Keratin1 antibody
    • KRT 1 antibody
    • Krt1 antibody
    • KRT1A antibody
    • NEPPK antibody
    • type II cytoskeletal 1 antibody
    • Type II keratin Kb1 antibody
    • Type-II keratin Kb1 antibody
    see all


This product has been referenced in:

  • de Berker D  et al. Keratin expression in discoid lupus erythematosus. Exp Dermatol 4:350-6 (1995). Read more (PubMed: 8608342) »
  • Ishida-Yamamoto A  et al. Epidermolysis bullosa simplex (Dowling-Meara type) is a genetic disease characterized by an abnormal keratin-filament network involving keratins K5 and K14. J Invest Dermatol 97:959-68 (1991). Read more (PubMed: 1721080) »
See all 2 Publications for this product

Customer reviews and Q&As


I'm sorry to hear you are having a problem with ab9220 and ab18389. I was able to find out that the antibody ab18389 has been used in a paper by Ishida-Yamamoto A et al. 1991. Invest Derm. 97 (6); 959 where a detailed protocol is described, unfortunately I was unable to access this paper but I hope this can help you. I'm also trying to find the dilutions used for this antibody, I can confirm that ab9220 has been tested on frozen sections fixed with ice cold methanol/acetone for 5 min and was used neat or at 1:10 dilution (as it is unpurified tissue culture supernatant), is this the dilution range you tested? There are also several publications which have used ab9220: Vos JH et al. The expression of keratins, vimentin, neurofilament proteins, smooth muscle actin, neuron-specific enolase, and synaptophysin in tumors of the specific glands in the canine anal region. Vet Pathol 30:352-61 (1993). PubMed: 8212457 Vos JH et al. Immunohistochemistry with keratin monoclonal antibodies in canine tissues: urogenital tract, respiratory tract, (neuro-)endocrine tissues, choroid plexus and spinal cord. Zentralbl Veterinarmed A 39:721-40 (1992). PubMed: 1283472 Wetzels RH et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 138:751-63 (1991). PubMed: 1705754 I hope this information will help you and will let you know the dilution used for ab18389 as soon as I find out,

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up